Clinical trial
PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
NCT00088413 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00088413 |
|---|---|
| Title | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer |
| Official title | An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Combination With Sargramostim in Adults With Metastatic Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | PANVAC-V, PANVAC-F, Sargramostim (GM-CSF, Leukine) |
| Enrollment | 51 |
| Start date | Jul 21, 2004 |
| Primary completion | Apr 1, 2018 |
| Completion | May 31, 2018 |
| First posted | Jul 26, 2004 |
| Last update posted | Apr 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: